
# Marijuana, high potency cannabis, and synthetic cannabinoids: increasing risk for psychosis?

Robin M Murray and Marta Di Forti Institute of Psychiatry, London, UK

robin.murray@kcl.ac.uk


# Drug Use can increase risk of Schizoprenia



Callaghan et al followed up methamphetamine abusers admitted to hospital in California and showed that they had a ninefold increase of subsequent schizophrenia

American Journal of Psychiatry, 2012

# Psychopathology of individuals with methamphetamine psychosis



# Other stimulants which increase risk of psychosis







Khat - Cathinone

Methylmethylcathinone (MMCat or miew-miew)

# Which drug do you have to use to become President?




bonga os





# Risk of psychosis in relation to extent of cannabis use




#### **Cohort Studies**

Country	<u>n</u>	<u>FU</u>	OR	
Sweden	50,053	25 yrs	3.1	
NL	4,045	3 yrs	2.8	
NL	4,045	3 yrs	12.0	
NL	18,000	Retro	3.2	
NZ (Chr)	1,265	3 yrs	1.8	
NZ (Dun)	1,253	15 yrs	3.1	
Germany	2,436	4 yrs	1.7	
UK	8,500	18 mths	1.5	
Australia	3,800	14 yrs	2.2	


#### Swedish Army Study of Andréasson et al 1987





## Risk of schizophreniform psychosis at age 26 years






Arseneault et al BMJ 2002

# IV administration of 2.5 mg of Tetrahydrocannabinol (THC) induces transient psychotic symptoms.

#### INVESTIGATOR RATED POSITIVE PSYCHOTIC SYMPTOMS



Morrison et al, 2009



# 121 schizotypal individuals were randomised to receive THC or placebo







Mean (S.D.) Paranoia Score

after Placebo 6.8 (9.8) after THC 15.6 (17.3)

## The ingredients of cannabis

Tetrahydrocannabinol (THC)


– partial agonist at CB1




Impairment of attention, memory and learning Hallucinations and paranoid ideas

THC

Cannabidiol (CBD)




Is not hallucinogenic
Has anxiety relieving properties
Antipsychotic actions?
Antagonise effects of THC?
CBD






# Psychotogenic effect of acute administration of 2.5 mg of IV Tetrahydrocannabinol (THC).

INVESTIGATOR RATED POSITIVE PSYCHOTIC SYMPTOMS



CBD or Placebo versus THC



**THC** induces transient psychotic symptoms

Cannabidiol (CBD) blocks the effects of THC

Morrison et al, 2009 Bhattacharyya et al 2010, Englund et al, 2012

#### Cannabidiol as an Antipsychotic?

Droopt

GW Pharmaceuticals Announces Positive Proof of Concept Data in Schizophrenia
15 September 2015

Placebo-controlled trial of addition of Cannabidiol (CBD) to standard antipsychotic in 88 patients with schizophrenia who had previously failed to respond adequately.

CBD was consistently superior to placebo, with the most notable differences being in the PANSS positive sub-scale (p=0.018).



## Increase in the potency of cannabis – the development of skunk!

When Ronald Reagan began a crackdown on illegal drugs, Tom Watson (the Skunkman) fled the USA in 1985 and brought his seeds to Amsterdam where

he could experiment with his plants more openly.


Indoor cultivation of cannabis was just starting to take off in the Netherlands, so he joined up with local cannabis experts to "breed" more potent plants

The Skunkman is said to be the father of "skunk"—a smelly hybrid of three previously uncrossed cannabis genetic lines.





## Cannabis potency in England



## The ingredients of cannabis

#### THC causes


Impairment of attention, memory and learning Hallucinations and paranoid ideas

#### Cannabidiol (CBD)

Is not hallucinogenic

Has anxiety relieving properties

No adverse effect on cognition





# Case-control study of cannabis and psychosis



•410 patients in their 1st episode of psychosis.

•370 population-based healthy controls (screened for psychosis)

All interviewed using the cannabis experience questionnaire



Di Forti et al, BJPsych 2009; Schiz Bull 2013





## Patterns of Cannabis Use

	Ever used (%)	Daily (% users)	Skunk (% users)
First episode Psychosis (n=410)	63.3	46.1	80.9
Controls (n=370)	63.4	18.7	42.6
	NS	<0.001	<0.001



### Skunk and its frequency of use






Figure 2: Probability of individuals having a psychotic disorder by pattern of cannabis use OR adjusted for age, gender, ethnic origin, education, employment status, and tobacco use. OR=odds ratio. \*p<0.05.

Embargo: February 18, 2015, NIHR funding

Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a



# Are cannabis using schizophrenics different from non using schizophrenics?


Users have an earlier onset

Users have a higher IQ

Users have better pre-morbid social functioning

# If cannabis using psychotic patients are a discrete group, they should be different from non-using psychotic patients

Users had an earlier onset of psychosis




Users had a higher pre-morbid IQ and better pre-morbid social function


Continued users had a worse outcome



## Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users

Marta Di Forti\*, Hannah Sallis², Fabio Allegri³, Antonella Trotta¹, Laura Ferraro⁴, Simona A. Stilo⁵, Arianna Marconi¹, Caterina La Cascia⁴, Tiago Reis Marques¹, Carmine Pariante⁶, Paola Dazzan¹, Valeria Mondelli⁶, Alessandra Paparelli¹, Anna Kolliakou¹, Diana Prata¹, Fiona Gaugrhan¹, Anthony S. David¹, Craig Morgan⁵, Daniel Sthal⁵, Mizanur Khondoker⁵, James H. MacCabe¹, and Robin M. Murray¹,8





#### **ONLINE FIRST**

## Cannabis Use and Earlier Onset of Psychosis

#### A Systematic Meta-analysis

Matthew Large, BSc(Med), MBBS, FRANZCP; Swapnil Sharma, MBBS, FRANZCP; Michael T. Compton, MD, MPH; Tim Slade, PhD; Olav Nielssen, MBBS, MCrim, FRANZCP

**Context:** A number of studies have found that the use of cannabis and other psychoactive substances is associated with an earlier onset of psychotic illness.

**Data Synthesis:** Meta-analysis found that the age at onset of psychosis for cannabis users was 2.70 years younger (standardized mean difference=-0.414) than for nonusers for those with broadly defined substance use the age

### Daily use and skunk use bring onset further

# Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis




Tabea Schoeler, Anna Monk, Musa B Sami, Ewa Klamerus, Enrico Foglia, Ruth Brown, Giulia Camuri, A Carlo Altamura, Robin Murray, Sagnik Bhattacharyya

Lancet Psychiatry 2016


Published Online January 14, 2016 http://dx.doi.org/10.1016/ S2215-0366(15)00363-6

Interpretation Continued cannabis use after onset of psychosis predicts adverse outcome, including higher relapse rates, longer hospital admissions, and more severe positive symptoms than for individuals who discontinue cannabis use and those who are non-users. These findings point to reductions in cannabis use as a crucial interventional target to improve outcome in patients with psychosis.

Incidence of First Episode Psychosis across 16 sites - ranged from 12.0 per 100,000 person years in Palermo to 63.9 per 100,000 in London




# Use of High Potency Cannabis (TCH>10%) in 1600 Cases of First Episode Psychosis and 1383 Populations Controls



\*\*p<0.001\*p<0.05OR Adj for age, gender, ethnicity, other drugs

## Gene-Environment Interaction



## Gene-Environment Interaction





Figure 1a. Interaction between *DRD2* rs1076560/*AKT1* rs2494732 and lifetime cannabis use on psychosis risk



<i>DRD2</i> rs1076560/ <i>AKT1</i> rs2494732	No cannabis use	Cannabis use
	Adj OR * 95% CI P value	Adj OR * 95% Cl P value
No "risk" alleles	1	1
One "risk" allele	0.29 0.09, 0.88 0.03	3.50 1.14, 10.77 0.03
Two "risk" alleles	0.14 0.03, 0.63 0.01	3.07 1.58, 33.64 0.01

Colizzi, et al Nature SCZ 2015

# The arrival of synthetic cannabinoids puts the psychotogenic effect beyond doubt



#### REVIEW



#### Spicing things up: synthetic cannabinoids

Max Spaderna · Peter H. Addy · Deepak Cyril D'Souza

While THC is a partial agonist at the CB1 Receptor, synthetic Cannabinoids are full agonists. Therefore they have much more powerful effects

Users are 30 times more likely to seek emergency treatment than users of regular cannabis

Winstock A, Global Drug Survey 2014

Hum. Psychopharmacol Clin Esp 2013; 28: 379–389. Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/bup.2312

SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES

"Spiceophrenia": a systematic overview of "Spice"-related psychopathological issues and a case report

Duccio Papanti<sup>1,2</sup>a, Fabrizio Schifano<sup>3</sup>, Giulia Botteon<sup>1,2</sup>, Francesca Bertossi<sup>4</sup>, Jason Mannix<sup>5</sup>, Daniela Vidoni<sup>6</sup>, Matteo Impagnatiello<sup>2</sup>, Elisabetta Pascolo-Fabrici<sup>1,2</sup> and Tommaso Bonavigo<sup>1,4</sup>



### Strange fame for an Academic



In 1984 Professor JW Huffman in Clemson Univ, USA began developing cannabinoid compounds to aid in research into multiple sclerosis, AIDS, and chemotherapy. Over twenty years, Huffman and his team developed 450 synthetic cannabinoid compounds.

In the late 2000s, Huffman's cannabinoid compounds began being sold in Germany as marijuana alternatives known as K2 and Spice .....JWH-018 etc.

"It bothers me that people are so stupid as to use this stuff".

#### CAUTION:

For fragrance purposes only.

Not for consumption.

Keep out of reach of children and pets.

Never leave burning incense unattended and make sure all ashes fall in ashtrays or burners.


### Burn in a well-ventilated area.

Smoke inhilation may cause light-headedness and be harmful to your health.

# Excess Synthesis of Striatal Dopamine



## **Psychosis**




Striatal dopamine neuron

Post-synaptic receptor

# Excess Synthesis of Striatal Dopamine



## **Psychosis**




Striatal dopamine neuron

AKT1 is a Kinase Protein involved in the transmission of the DRD2 signaling


Post-synaptic receptor

#### Effect of chronic THC on DA transmission in rats



Nathalie Ginovart et al. Neuropsycholopharmacology 2012

Striatal dopamine synthesis capacity in regular cannabis users vs. nonusers



Abi-Dhargum group showed that in cannabis-induced psychosis, striatal DA was low but even a small increase precipitated psychotic symptoms

#### COMMENTARY

#### Different Dopaminergic Abnormalities Underlie Cannabis Dependence and Cannabis-Induced Psychosis

Robin M. Murray, Mitul Mehta, and Marta Di Forti

Chronic cannabis use induces low striatal dopamine – similar to other drug dependencies, but also the concurrent development of post-synaptic super-sensitivity

### Conclusions

- Administering THC can induce an acute psychosis; this effect is moderated by CBD.
- 2) Heavy use of cannabis, especially high potency varieties, is associated with greater later risk of psychosis.
- 3) Cannabis-using psychotic patients have an earlier onset, and better premorbid function than non-using psychotic patients; they have a worse outcome if they continue to use cannabis
- 4) There is preliminary evidence that some people are genetically vulnerable

Thanks to:

The GAP and EU-GEI

Teams, and especially

Paul Morrison

Amir Englund

Marco Colizzi

**Evangelos Vassos** 

Jim Van Os



and all our patients